Reported Earlier, Gilead Sciences Prices $3B Senior Unsecured Notes In Four Tranches: $500M At 4.250% Due 2028, $1B At 4.400% Due 2029, $1B At 4.600% Due 2031 And $500M At 4.900% Due 2034

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include funding for acquisitions, investments, strategic transactions or other business opportunities.